Lobe Sciences CEO touts targeted low dosing for better patient outcomes


Journey to treatment: Lobe Sciences CEO touts targeted low dose for better patient outcomesYoutube

Lobe Sciences (CSE:LOBE,OTCQB:LOBEF) takes a different approach to psychedelic treatment using low-dose sub-psychedelic stimulation targeting the right receptor to achieve better patient outcomes.

“Our whole philosophy is that we don’t believe you have to go on a psychedelic trip to benefit from therapeutic interventions,” said Lobe Sciences CEO Philip J. Young. “The business model where patients are confined to a clinic for eight to 12 hours and undergo a psychedelic trip, is not for me the best way to create a global pharmaceutical market.”

Lobe Sciences is a life sciences company focused on the research and development of psychedelic drugs to treat neurological disorders and trauma. The company has made progress in developing a psilocybin-based treatment for anxiety disorders and is also targeting a treatment for a pediatric orphan disease indication.

“Children really need therapeutic intervention and support,” Young explained.

“We are now in a position where we control our drug supply. We have clinical development plans, and we will actually dose our first patient in clinical trials this month,” he said.

Young said his company is about to submit an investigational new drug application to the U.S. Food and Drug Administration for its orphan disease drug for a pediatric indication. It will also begin its first human study using its proprietary compounds.

Lobe Sciences recently expanded its patent portfolio by filing international patents for methods and devices that treat mild traumatic brain injury and post-traumatic stress disorder.

Watch the full interview with Lobe Sciences CEO Philip J. Young above.

Disclaimer: This interview is sponsored by Lobe Sciences (CSE: LOBE, OTCQB: LOBEF). This interview provides information sourced from the Investing News Network (INN) and approved by Lobe Science to help investors get to know the company better. Lobe Science is an INN customer. Company campaign fees allow INN to create and update this interview.

INN does not provide investment advice and the information in this profile should not be considered a recommendation to buy or sell any securities. INN does not endorse or recommend the activities, products, services or securities of any company featured.

The information contained herein is for informational purposes only and should not be construed as an offer or solicitation to sell or buy any securities. Readers should do their own research for all publicly available information regarding the company. Before making any investment decision, readers are advised to consult directly Lobe Science and seek advice from a qualified investment advisor.

This interview may contain forward-looking statements, including, but not limited to, comments regarding the timing and content of upcoming work programs, receipt of title deeds, etc. Forward-looking statements relate to future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in these statements. The issuer relies on litigation protection for forward-looking statements. Investing in companies involves uncertainties as market values ​​can fluctuate.


Comments are closed.